Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
35,033
archived clinical trials in
Lung Cancer

A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/5/2014
Clinical Research Facility
942
mi
from 98109
Oxnard, CA
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/5/2014
Clinical Research Facility
942
mi
from 98109
Oxnard, CA
Click here to add this to my saved trials
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/5/2014
Clinical Research Facility
1733
mi
from 98109
Chicago, IL
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/5/2014
Clinical Research Facility
1733
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/5/2014
Clinical Research Facility
1813
mi
from 98109
Lafayette, IN
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/5/2014
Clinical Research Facility
1813
mi
from 98109
Lafayette, IN
Click here to add this to my saved trials
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/5/2014
Clinical Research Facility
2035
mi
from 98109
Baton Rouge, LA
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/5/2014
Clinical Research Facility
2035
mi
from 98109
Baton Rouge, LA
Click here to add this to my saved trials
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/5/2014
Clinical Research Facility
2343
mi
from 98109
Annapolis, MD
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/5/2014
Clinical Research Facility
2343
mi
from 98109
Annapolis, MD
Click here to add this to my saved trials
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/5/2014
Clinical Research Facility
2485
mi
from 98109
Boston, MA
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/5/2014
Clinical Research Facility
2485
mi
from 98109
Boston, MA
Click here to add this to my saved trials
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/5/2014
Clinical Research Facility
2484
mi
from 98109
Danvers, MA
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/5/2014
Clinical Research Facility
2484
mi
from 98109
Danvers, MA
Click here to add this to my saved trials
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/5/2014
Clinical Research Facility
1366
mi
from 98109
Omaha, NE
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/5/2014
Clinical Research Facility
1366
mi
from 98109
Omaha, NE
Click here to add this to my saved trials
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/5/2014
Clinical Research Facility
2414
mi
from 98109
Lake Success, NY
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/5/2014
Clinical Research Facility
2414
mi
from 98109
Lake Success, NY
Click here to add this to my saved trials
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/5/2014
Clinical Research Facility
2052
mi
from 98109
Canton, OH
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/5/2014
Clinical Research Facility
2052
mi
from 98109
Canton, OH
Click here to add this to my saved trials
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/5/2014
Clinical Research Facility
2006
mi
from 98109
Dover, OH
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/5/2014
Clinical Research Facility
2006
mi
from 98109
Dover, OH
Click here to add this to my saved trials
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/5/2014
Clinical Research Facility
2293
mi
from 98109
Hershey, PA
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/5/2014
Clinical Research Facility
2293
mi
from 98109
Hershey, PA
Click here to add this to my saved trials
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/5/2014
Research Site
2411
mi
from 98109
Hilton Head, SC
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/5/2014
Research Site
2411
mi
from 98109
Hilton Head, SC
Click here to add this to my saved trials
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/5/2014
Clinical Research Facility
1916
mi
from 98109
Corpus Christi, TX
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/5/2014
Clinical Research Facility
1916
mi
from 98109
Corpus Christi, TX
Click here to add this to my saved trials
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/5/2014
2188
mi
from 98109
Ottawa,
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/5/2014
2188
mi
from 98109
Ottawa,
Click here to add this to my saved trials
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113
Status: Enrolling
Updated:  4/11/2014
University of California at San Diego Moores Cancer Center
1065
mi
from 98109
San Diego, CA
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113
Status: Enrolling
Updated: 4/11/2014
University of California at San Diego Moores Cancer Center
1065
mi
from 98109
San Diego, CA
Click here to add this to my saved trials
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113
Status: Enrolling
Updated:  4/11/2014
University of Colorado Hospital
1029
mi
from 98109
Aurora, CO
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113
Status: Enrolling
Updated: 4/11/2014
University of Colorado Hospital
1029
mi
from 98109
Aurora, CO
Click here to add this to my saved trials
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113
Status: Enrolling
Updated:  4/11/2014
Yale University
2432
mi
from 98109
New Haven, CT
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113
Status: Enrolling
Updated: 4/11/2014
Yale University
2432
mi
from 98109
New Haven, CT
Click here to add this to my saved trials
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113
Status: Enrolling
Updated:  4/11/2014
University of Chicago Medical Center
1737
mi
from 98109
Chicago, IL
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113
Status: Enrolling
Updated: 4/11/2014
University of Chicago Medical Center
1737
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113
Status: Enrolling
Updated:  4/11/2014
Mass General Hospital (MGH)
2485
mi
from 98109
Boston, MA
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113
Status: Enrolling
Updated: 4/11/2014
Mass General Hospital (MGH)
2485
mi
from 98109
Boston, MA
Click here to add this to my saved trials
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113
Status: Enrolling
Updated:  4/11/2014
Ohio State University Comprehensive Cancer Center
2006
mi
from 98109
Columbus, OH
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113
Status: Enrolling
Updated: 4/11/2014
Ohio State University Comprehensive Cancer Center
2006
mi
from 98109
Columbus, OH
Click here to add this to my saved trials
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113
Status: Enrolling
Updated:  4/11/2014
Univ of Pennsylvania
2371
mi
from 98109
Philadelphia, PA
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113
Status: Enrolling
Updated: 4/11/2014
Univ of Pennsylvania
2371
mi
from 98109
Philadelphia, PA
Click here to add this to my saved trials
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113
Status: Enrolling
Updated:  4/11/2014
University of Texas M.D. Anderson Cancer Center
1892
mi
from 98109
Houston, TX
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113
Status: Enrolling
Updated: 4/11/2014
University of Texas M.D. Anderson Cancer Center
1892
mi
from 98109
Houston, TX
Click here to add this to my saved trials
AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer
A Phase I/II Trial of AMG 102 and Erlotinib in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  4/14/2014
University of Pittsburgh Cancer Institute
2135
mi
from 98109
Pittsburgh, PA
AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer
A Phase I/II Trial of AMG 102 and Erlotinib in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 4/14/2014
University of Pittsburgh Cancer Institute
2135
mi
from 98109
Pittsburgh, PA
Click here to add this to my saved trials
Validation of the MiCK Assay
Mayo Clinic Validation of the MiCK Assay
Status: Enrolling
Updated:  4/18/2014
Mayo Validation Support Services 3050 Superior Drive NW
1450
mi
from 98109
Rochester, MN
Validation of the MiCK Assay
Mayo Clinic Validation of the MiCK Assay
Status: Enrolling
Updated: 4/18/2014
Mayo Validation Support Services 3050 Superior Drive NW
1450
mi
from 98109
Rochester, MN
Click here to add this to my saved trials
A Protocol of Irinotecan for Carcinoma of the Lung
A Non-randomized Phase II Protocol of Irinotecan for Patients With Previously Treated, Advanced ISG15-positive Non-small Cell Carcinoma of the Lung
Status: Enrolling
Updated:  4/28/2014
University of Kentucky, Markey Cancer Center
2005
mi
from 98109
Lexington, KY
A Protocol of Irinotecan for Carcinoma of the Lung
A Non-randomized Phase II Protocol of Irinotecan for Patients With Previously Treated, Advanced ISG15-positive Non-small Cell Carcinoma of the Lung
Status: Enrolling
Updated: 4/28/2014
University of Kentucky, Markey Cancer Center
2005
mi
from 98109
Lexington, KY
Click here to add this to my saved trials
Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Therapy Containing Bevacizumab
A Multi-Center Open Label Phase II Study of Pazopanib in Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer After Progression on First Line Therapy Containing Bevacizumab
Status: Enrolling
Updated:  5/13/2014
North Carolina Cancer Hospital at U of North Carolina at CH
2329
mi
from 98109
Chapel Hill, NC
Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Therapy Containing Bevacizumab
A Multi-Center Open Label Phase II Study of Pazopanib in Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer After Progression on First Line Therapy Containing Bevacizumab
Status: Enrolling
Updated: 5/13/2014
North Carolina Cancer Hospital at U of North Carolina at CH
2329
mi
from 98109
Chapel Hill, NC
Click here to add this to my saved trials
Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Therapy Containing Bevacizumab
A Multi-Center Open Label Phase II Study of Pazopanib in Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer After Progression on First Line Therapy Containing Bevacizumab
Status: Enrolling
Updated:  5/13/2014
Rex Cancer Center at Rex Hospital
2358
mi
from 98109
Raleigh, NC
Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Therapy Containing Bevacizumab
A Multi-Center Open Label Phase II Study of Pazopanib in Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer After Progression on First Line Therapy Containing Bevacizumab
Status: Enrolling
Updated: 5/13/2014
Rex Cancer Center at Rex Hospital
2358
mi
from 98109
Raleigh, NC
Click here to add this to my saved trials
Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Therapy Containing Bevacizumab
A Multi-Center Open Label Phase II Study of Pazopanib in Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer After Progression on First Line Therapy Containing Bevacizumab
Status: Enrolling
Updated:  5/13/2014
University of Pittsburgh Medical Center
2134
mi
from 98109
Pittsburgh, PA
Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Therapy Containing Bevacizumab
A Multi-Center Open Label Phase II Study of Pazopanib in Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer After Progression on First Line Therapy Containing Bevacizumab
Status: Enrolling
Updated: 5/13/2014
University of Pittsburgh Medical Center
2134
mi
from 98109
Pittsburgh, PA
Click here to add this to my saved trials
Free Fatty Acid Metabolite Biomarkers for Cancer
Status: Enrolling
Updated:  5/14/2014
Cleveland Clinic
2024
mi
from 98109
Cleveland, OH
Free Fatty Acid Metabolite Biomarkers for Cancer
Status: Enrolling
Updated: 5/14/2014
Cleveland Clinic
2024
mi
from 98109
Cleveland, OH
Click here to add this to my saved trials
Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer
Phase I Dose Escalation Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab in Stage IV Non-Squamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  5/19/2014
Cancer Research And Biostatistics Clinical Trials Consortium
2
mi
from 98109
Seattle, WA
Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer
Phase I Dose Escalation Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab in Stage IV Non-Squamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 5/19/2014
Cancer Research And Biostatistics Clinical Trials Consortium
2
mi
from 98109
Seattle, WA
Click here to add this to my saved trials
Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer
Phase I Dose Escalation Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab in Stage IV Non-Squamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  5/19/2014
Providence Cancer Center
145
mi
from 98109
Portland, OR
Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer
Phase I Dose Escalation Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab in Stage IV Non-Squamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 5/19/2014
Providence Cancer Center
145
mi
from 98109
Portland, OR
Click here to add this to my saved trials
Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer
Phase I Dose Escalation Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab in Stage IV Non-Squamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  5/19/2014
The University of Arizona Cancer Center
1207
mi
from 98109
Tuscon, AZ
Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer
Phase I Dose Escalation Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab in Stage IV Non-Squamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 5/19/2014
The University of Arizona Cancer Center
1207
mi
from 98109
Tuscon, AZ
Click here to add this to my saved trials
Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer
Phase I Dose Escalation Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab in Stage IV Non-Squamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  5/19/2014
University of Kentucky, Markey Cancer Center
2005
mi
from 98109
Lexington, KY
Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer
Phase I Dose Escalation Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab in Stage IV Non-Squamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 5/19/2014
University of Kentucky, Markey Cancer Center
2005
mi
from 98109
Lexington, KY
Click here to add this to my saved trials
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer
Status: Enrolling
Updated:  6/27/2014
H. Lee Moffitt Cancer Center
2522
mi
from 98109
Tampa, FL
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer
Status: Enrolling
Updated: 6/27/2014
H. Lee Moffitt Cancer Center
2522
mi
from 98109
Tampa, FL
Click here to add this to my saved trials
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer
Status: Enrolling
Updated:  6/27/2014
Barbara Ann Karmanos Cancer Institute
1932
mi
from 98109
Detroit, MI
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer
Status: Enrolling
Updated: 6/27/2014
Barbara Ann Karmanos Cancer Institute
1932
mi
from 98109
Detroit, MI
Click here to add this to my saved trials
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer
Status: Enrolling
Updated:  6/27/2014
Roswell Park Cancer Institute
2110
mi
from 98109
Buffalo, NY
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer
Status: Enrolling
Updated: 6/27/2014
Roswell Park Cancer Institute
2110
mi
from 98109
Buffalo, NY
Click here to add this to my saved trials
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer
Status: Enrolling
Updated:  6/27/2014
Scottsdale Healthcare
1113
mi
from 98109
Scottsdale, AZ
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer
Status: Enrolling
Updated: 6/27/2014
Scottsdale Healthcare
1113
mi
from 98109
Scottsdale, AZ
Click here to add this to my saved trials
Pilot Study of a Novel Type of CT Scan to Assess Treatment Response During Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer
Pilot Study of Dual-Energy Computed Tomography in Stage III Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  8/29/2014
Rush University Medical Center
1730
mi
from 98109
Chicago, IL
Pilot Study of a Novel Type of CT Scan to Assess Treatment Response During Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer
Pilot Study of Dual-Energy Computed Tomography in Stage III Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 8/29/2014
Rush University Medical Center
1730
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated:  9/18/2014
Cardiopulmonary Research Science & Technology Institute
1681
mi
from 98109
Dallas, TX
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated: 9/18/2014
Cardiopulmonary Research Science & Technology Institute
1681
mi
from 98109
Dallas, TX
Click here to add this to my saved trials
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated:  9/18/2014
Geisinger Medical Center
2273
mi
from 98109
Danville, PA
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated: 9/18/2014
Geisinger Medical Center
2273
mi
from 98109
Danville, PA
Click here to add this to my saved trials
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated:  9/18/2014
Greater Baltimore Medical Center
2323
mi
from 98109
Baltimore, MD
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated: 9/18/2014
Greater Baltimore Medical Center
2323
mi
from 98109
Baltimore, MD
Click here to add this to my saved trials
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated:  9/18/2014
Group Health Research Institute
1
mi
from 98109
Seattle, WA
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated: 9/18/2014
Group Health Research Institute
1
mi
from 98109
Seattle, WA
Click here to add this to my saved trials
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated:  9/18/2014
Henry Ford Hospital
1930
mi
from 98109
Detroit, MI
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated: 9/18/2014
Henry Ford Hospital
1930
mi
from 98109
Detroit, MI
Click here to add this to my saved trials
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated:  9/18/2014
Intermountain Healthcare
706
mi
from 98109
Murray, UT
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated: 9/18/2014
Intermountain Healthcare
706
mi
from 98109
Murray, UT
Click here to add this to my saved trials
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated:  9/18/2014
Kaiser Permanente Northern California
680
mi
from 98109
San Francisco, CA
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated: 9/18/2014
Kaiser Permanente Northern California
680
mi
from 98109
San Francisco, CA
Click here to add this to my saved trials
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated:  9/18/2014
Lahey Hospital and Medical Center
2475
mi
from 98109
Burlington, MA
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated: 9/18/2014
Lahey Hospital and Medical Center
2475
mi
from 98109
Burlington, MA
Click here to add this to my saved trials
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated:  9/18/2014
Mayo Clinic Rochester
1450
mi
from 98109
Rochester, MN
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated: 9/18/2014
Mayo Clinic Rochester
1450
mi
from 98109
Rochester, MN
Click here to add this to my saved trials
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated:  9/18/2014
North East Alabama Regional Medical Center
2121
mi
from 98109
Anniston, GA
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated: 9/18/2014
North East Alabama Regional Medical Center
2121
mi
from 98109
Anniston, GA
Click here to add this to my saved trials
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated:  9/18/2014
University of Cincinnati
1967
mi
from 98109
Cincinnati, OH
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated: 9/18/2014
University of Cincinnati
1967
mi
from 98109
Cincinnati, OH
Click here to add this to my saved trials